The Expression of Insulin-Like Growth Factor 2 Messenger RNA-Binding Protein 3 in Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma

Yashige, Konomi; Kataoka, Tatsuki R.; Yamada, Yosuke; Maeda, Hatsuo; Oji-Tsujimura, Marina; Yamamoto, Tetsurou; Takei, Yutaka; Moriyoshi, Koki; Ôno, Kazuo; Kaku, Yo; Tabata, Tetsuya; Murakami, Ichiro; Nakamine, Hirokazu; Haga, Hironori

doi:10.1620/tjem.255.27

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGF2BP3 is expressed in malignant cells with aggressive or proliferative phenotypes, and is thought to be related to expression of cyclins A, B1, and D1 ( 11 ), It has been reported that IGF2BP3 may be the key factor to distinguish LCH from LCS, and may become a prognostic marker. In our patient, IGF2BP3 showed high expression ( 12 ).…”

Section: Discussionmentioning

confidence: 47%

Case Report: Langerhans Cell Sarcoma With Intracranial and Extracranial Communication on the Left Frontal Bone

Xie

Shao

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

BackgroundLangerhans cell sarcoma (LCS) is an extremely rare type of malignant tumor that originates from Langerhans cells (LC). It is characterized by the malignant proliferation and dissemination of LC and is extremely invasive, with rapid progression and a poor prognosis. Treatment includes resection of lesions, radiotherapy, chemotherapy, immunotherapy, and transplantation of hematopoietic stem cells. However, a unified and optimized treatment plan is lacking, and individualized treatment is accepted.Case presentationWe report an 18-year-old man with intracranial and extracranial communicative LCS that occurred in only the left forehead without metastasis to other regions. Clinical and hematological data were normal. We undertook complete resection of diseased tissue, which was pathologically examined. Staining (hematoxylin and eosin) showed positivity for cluster of differentiation (CD)1a (++), S-100 protein (++), P53 (++), CD68 (+), cyclin D1 (+), cyclin A (+), cyclin B1 (+), IGF2BP3 (+), and Ki-67 (45%–50%). Recurrence or metastasis were not observed after long-term follow-up.ConclusionLCS is a rare malignant tumor, and one that occurs with intracranial and extracranial communication is even rarer. Active adoption of an individualized treatment plan is crucial.

show abstract

Section: Discussionmentioning

confidence: 47%